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Abstract – Methyl 
4-deoxy-4-dimethoxyphosphinoyl-2,3-O-isopropylidene-β-D-ribopyranoside 
(12a) and methyl 
2,4-dideoxy-4-dimethoxyphosphinoyl-β-D-erythro-pentopyranoside (20) were 
efficiently prepared respectively from methyl 
2,3-O-isopropylidene-β-D-ribopyranoside (7a) and its 3,4-O-isopropylidene 
isomer (7b) in appreciably improved total yields compared with those via 
previously reported routes.  Compounds (12a, 20) were led to D-ribofuranose 
and 2-deoxy-D-ribofuranose phospho sugars (4, 5).
INTRODUCTION 
Sugar analogs having carbon,2 nitrogen,3 sulfur,4 or phosphorus5 in place of the ring oxygen have been 
prepared because of the wide interest in their chemical and biochemical properties.  In view of such a 
chemical modification by carbon and heteroatoms, synthesis and biological activities of various 
nucleosides of carba, imino and thio sugars have been reported.6  For examples, aristeromycin (1) 
terminates viral growth by inhibiting S-adenosyl-L-homocysteine hydrolase,7 whereas oligonucleotides 
containing 4’-acetamido-4’-deoxythymidine (2) show considerable resistance to degradation by 
3’-exonucleases8 and 4’-thiothymidine (3) is a potent inhibitor of leukemia L1210 cell growth.9  
Although no corresponding nucleosides of phospho sugars have been made so far, D-ribofuranose-type 
(4)10 and 2-deoxy-D-ribofuranose-type phospho sugars (5)11,12 are considered to be highly of interest as 
potential precursors for phospho sugar nucleosides. 
  
In the first synthesis of 4,10 the key intermediate 4-deoxy-4-phosphinoyl-D-ribopyranoside derivative 
(12a) was prepared by starting with methyl 2,3-O-isopropylidene-β-D-ribopyranoside (7a), a minor 
component obtained by acetalization of methyl β-D-ribopyranoside (6) (Scheme 1).  In this route, the 
introduction of a phosphinoyl group onto sugar skeleton was accomplished by the addition of dimethyl 
phosphonate to the 4-tosylhydrazone derivative (9) and the subsequent reductive removal of the 
tosylhydrazino group of the addition product (10) with sodium borohydride.  Although the desired 
4-phosphinoyl-D-ribopyranoside derivative (12a) was obtained with relatively good diastereoselectivity 
(85:15), the total yields of 12a from 9 were rather low due to the simultaneous production of various 
by-products.  We thus attempted an improved synthesis of D-ribofuranose phospho sugar (4) by using 
our alternative procedure of C–P bond formation;13 i.e., addition of phosphonate to the 4-ulose (8) and the 
subsequent deoxygenation. 
In the mean time, 2-deoxy-D-ribofuranose phospho sugar (5) was prepared by two different routes from 
D-glucose by rather long steps including degradation of the sugar skeleton.11,12  We also report herein an 
improved synthesis of 5 via a shorter route by an effective use of methyl 
3,4-O-isopropylidene-β-D-ribopyranoside (7b), a major component obtained by acetalization of 6, as the 
starting material. 
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RESULTS AND DISCUSSION 
Acetalization of methyl β-D-ribopyranoside (6) with acetone-sulfuric acid has been reported to afford the 
2,3-O-isopropylidene derivative (7a) and its 3,4-O-isopropylidene isomer (7b) in 23% and 46% yields, 
respectively.14  Attempts to modify the acetalization by use of other reagents brought about improved 
yields of 7a and 7b but their ratio remained almost the same.  Namely, treatment of 6 with 
2,2-dimethoxypropane in the presence of hydrochloric acid at 20 °C provided 7a in 31% and 7b in 63%, 
while acetalization of 6 with 2-methoxypropene and p-toluenesulfonic acid in DMF at 0 °C resulted in the 
similar formation of the two isomers (7a: 32%, 7b: 62%). 
Swern oxidation of 7a with oxalyl chloride-DMSO afforded the D-erythro-pentopyranosid-4-ulose (8) in 
92% yield (Scheme 2).  The addition reaction of dimethyl phosphonate to 8 in the presence of DBU 
gave a sole product (in 98% yield), whose structure was assigned to be the 
(4S)-4-C-dimethoxyphosphinoyl derivative (11) on the basis of 1H NMR spectra (see below).  
Compound (11) was converted to the methoxalyl esters with methoxalyl chloride in the presence of 
4-dimethylaminopyridine (DMAP) and the subsequent reduction with tributyltin hydride in the presence 
of AIBN15 mainly afforded the desired 4-deoxy-4-phosphinoyl-D-ribopyranoside derivative (12a) (54%) 
together with a minor proportion of the L-lyxopyranoside derivative (12b) (18%).16 
The conversion of the major product (12a) into 4-deoxy-4-hydroxyphosphonoyl-D-ribofuranose (4) was 
made according to the reported procedures10 with a slight modification: reduction of 12a with sodium 
dihydrobis(2-methoxyethoxy)aluminate (SDMA) in toluene at 0 °C, followed by hydrolysis with 
hydrochloric acid and then oxidation with hydrogen peroxide, afforded 4.  For isolation and 
characterization, 4 was converted into the corresponding 4-(methoxyphosphonoyl) tetraacetates (13) by 
treatment with acetic anhydride-pyridine and then ethereal diazomethane in improved yields; 
4-[(R)-methoxyphosphonoyl]-α-isomer (13a) (6.3% overall yield from 12a), its β-anomer (13b) (12%), 
4-[(S)-methyoxyphosphonoyl]-α-isomer (13c) (3.2%), and its β-anomer (13d) (5.3%). 
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Preparation of 2-deoxy-D-ribofuranose phospho sugar (5) starting with methyl 
3,4-O-isopropylidene-β-D-ribopyranoside (7b) was similarly attempted (Scheme 3).  Methyl 
2-deoxy-β-D-erythro-pentopyranoside (15) was prepared from 7b via 14 according to the reported 
procedures.17  Mono-O-benzylation of 15 was carried out via the 3,4-O-stannylene acetal obtained by 
treatment of 15 with dibutyltin oxide in refluxing toluene.  The stannylene acetal was then subjected to 
the benzylation with benzyl bromide in the presence of tetrabutylammonium bromide in DMF at 
100 °C,18 providing the 3-O-benzyl derivative (16a) and the 4-O-benzyl isomer (16b) in 42% and 45% 
yields, respectively.  The yield of desired 16a was improved by practice of the same reaction in 
refluxing toluene;19 16a (55%), 16b (40%).  
 
 
Scheme 3 
 
The 3-O-benzyl compound (16a) was oxidized with oxalyl chloride-DMSO to give the 4-ulose (17), 
which was then treated with dimethyl phosphonate and DBU to provide the 
(4R)-4-dimethoxyphosphinoyl derivative (18a) and its (4S)-epimer (18b) as an inseparable mixture 
(53:47) in 93% yield.  By use of same procedures for 12 from 11, deoxygenation of 18a,b afforded the 
desired 2,4-dideoxy-4-phosphinoyl-D-erythro-pentopyranoside (19a) and its L-threo-isomer (19b) in 53% 
and 35% yields, respectively,16 although its stereoselectivity (60:40) was lower than that of 12 from 11 
(75:25). 
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 The C-4 configurations and conformational assignments of the 4-dimethoxyphosphinoyl compounds (11, 
12a,b and 18a,b, 19a,b) were established by the analysis of their 1H NMR data (Table 1).  The favored 
conformations of these compounds in CDCl3 are shown in Figure 1.  The D-ribo and D-erythro 
configurations of 12a and 19a, as well as their 4C1 conformation, were assigned on the basis of the small 
J3,4 (3–4 Hz) and the large J4,5S values (9–12 Hz).  Similarly, the L-lyxo and L-threo configurations (with 
1C4 conformations) of 12b and 19b were derived from the large J3,4 and J4,5R values (9–10 Hz).  
Although compounds (11 and 18b) have no H-4 proton, their (4R)-configurations and 1C4 conformations 
were assigned by respective comparison to the corresponding 4-deoxy compounds (12b and 19b), 
because a similar characteristic tendency of the corresponding coupling constants and the chemical shifts 
is expected owing to almost identical conformations.  For example, the presence of long-range couplings 
J2,P (for 11, 12b) and J2S,P (for 18b, 19b) indicates all of these compounds exist in the 1C4 conformations 
and have an equatorial phosphinoyl group, whereas the (4S)-epimer (18a) has the large J3,P and J5R,P 
values (20–21 Hz) and thus is considered to exist in the 1C4 conformation. 
 
Table 1.  1H and 31P NMR Parameters for Compounds (11, 12a,b, 18a,b, 19a,b) in CDCl3 
—————————————————————————————————————————————— 
Chemical shifts / δ 
Com-  ——————————————————————————————————————————— 
pound H-1 HR-2 HS-2 a H-3 H-4 HR-5 HS-5 MeO-1 POMe b Me2C CH2O-3 c HO-4 31P 
—————————————————————————————————————————————— 
11 4.89 – 4.09 4.58  – 3.80 3.95 3.42 3.87, 3.83 1.59, 1.40 – 3.07 23.3 
12a 4.38 – 3.92 4.62  2.73 3.92 3.83 3.46 3.77, 3.74 1.53, 1.38 – – 27.4 
12b 4.79 – 3.96 4.50 2.34  3.80 d 3.78 d 3.39 3.77, 3.765 1.52, 1.35 – – 29.6 
18a 4.63 2.28 2.05 3.96 – 3.71 4.01 3.38 3.78, 3.735 – 4.70, 4.56 e 3.75 25.7 
18b 4.81 1.96 2.06 4.28 – 3.78 3.92 3.33 3.74, 3.72 – 4.64, 4.61 f 3.75 24.6 
19a 4.71 2.26 1.58 3.96 2.39 3.99 4.01 3.44 3.69, 3.62 – 4.64, 4.625 e – 29.9 
19b 4.81 1.60 2.26 4.14 2.29 3.88 3.86 3.32 3.71, 3.655 – 4.62, 4.56 f – 29.7 
—————————————————————————————————————————————— 
Coupling constants / Hz 
——————————————————————————————————————————— 
 J1,2R J1,2S J1,5S  J2R,2S J2R,3 J2R,P J2S,3 J2S,P J3,4 J3,P J4,5R J4,5S J4,P  J5R,5S J5R,P J5S,P  
—————————————————————————————————————————————— 
11  – 1.7 1.6 –  –  – 6.6 2.2  – 8.3  –  – – 12.5 4.5 1.0 
12a  – 4.9 0 –  –  – 6.3 0  2.9 3.6  5.6  11.8 23.7 11.3 1.2 4.3 
12b  – 2.0 2.0 –  –  – 5.2 2.2  8.6 11.3  8.9  5.1 18.8 d d d 
18a  3.4 4.7 0.8 13.4  8.6  0 4.6 0  – 21.0  –  –  – 12.0 20.0 6.6 
18b  3.4 1.5 1.8 12.9  11.2  1.0 5.1 5.1  – 4.2  –  –  – 12.9 4.0 1.5 
19a  2.7 7.8 0 13.7  5.1  4.6 3.2 0  3.7 13.4  4.6  8.8 20.8 11.8 9.5 4.8 
19b  3.4 2.2 2.2 12.9  10.5  0.7 4.4 5.6  10.0 8.1  10.3  5.9 17.1 11.7 3.4 4.4 
—————————————————————————————————————————————— 
a The parameters concerning H-2 of 11 and 12a,b are listed as HS-2.  b 2JPOMe = 10.7–11.0 Hz.  c δ = 7.37 [Ph(o)], 
7.34 [Ph(m)], 7.28 [Ph(p)].  d Uncertain because of overlapping with other signals.  e 2J = 11.5 Hz.  f 2J = 11.1 
Hz. 
  
 
Figure 1. Structures and favored conformations for the 4-dimethoxyphosphinoylpyranosides (11, 12a,b, 
 18a,b, and 19a,b) 
 
The hydrogenolysis of the major isomer (19a) in the presence of 10% Pd-C afforded methyl 
2,4-dideoxy-4-dimethoxyphosphinoyl-β-D-erythro-pentopyranoside (20) in 90% yield.  By use of same 
procedures described for 4 from 12a, compound (20) was converted into 2-deoxy-D-ribofuranose 
phospho sugar (5), which was characterized after having been converted into the corresponding 
4-methoxyphosphonoyl 1,3,5-tri-O-acetates (21): 4-[(R)-methoxyphosphonoyl]-α-isomer (21a) (5.2% 
overall yield from 20), its β-anomer (21b) (8.2%), 4-[(S)-methoxyphosphonoyl]-α-isomer (21c) (6.8%), 
and its β-anomer (21d) (9.9%). 
Thus, improved syntheses of 4 and 5 from the common starting material (6) were achieved via shorter 
routes involving alternative procedures to introduce a phosphinoyl group in better overall yields.  
Extension of this work including the improvement of stereoselectivity for C-P bond formation, as well as 
derivation of 4 and 5 into the corresponding nucleosides, is in progress. 
EXPERIMENTAL 
All reactions were monitored by TLC (Merck silica gel 60F, 0.25 mm) with an appropriate solvent system 
[(A) 1:2, (B) 2:1 AcOEt–hexane, and (C) AcOEt].  Column chromatography was performed with Daiso 
Silica Gel IR-60/210w.  Components were detected by exposing the plates to UV light and/or spraying 
them with 20% sulfuric acid–ethanol (with subsequent heating).  Optical rotations were measured with a 
Jasco P-1020 polarimeter in CHCl3.  The NMR spectra were measured in CDCl3 with Varian Unity 
Inova AS600 (600 MHz for 1H, 151 MHz for 13C) and Mercury 300 (121 MHz for 31P) spectrometer at 
23 °C.  Chemical shifts are reported as δ values relative to CHCl3 (7.26 ppm as an internal standard for 
1H), CDCl3 (77.0 ppm as internal standard for 13C), and 85% phosphoric acid (0 ppm as an external 
standard for 31P).  The assignments of 13C signals were made with the aid of 2D C-H COSY 
measurements. 
 
Methyl 2,3-O-isopropylidene-β-D-ribopyranoside (7a) and its 3,4-O-isopropylidene isomer (7b).14,17 
A. Acetalization with 2,2-dimethoxypropane-HCl.  To a solution of methyl β-D-ribopyranoside (6) 
(5.00 g, 30.3 mmol) in 2,2-dimethoxypropane (50 mL) was added 4M hydrochloric acid in 1,4-dioxane 
(1.50 mL).  The mixture was stirred at 25 °C for 1 h, neutralized with pyridine, and then concentrated in 
vacuo.  The residue was separated by column chromatography with 2:1 AcOEt-hexane to give 7a (1.91 
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 g, 31%) and 7b (3.88 g, 63%). 
7a: Colorless prisms, mp 70–71 °C (from AcOEt-hexane) (lit.,14 70–71 °C); Rf = 0.41 (B); 1H NMR20 δ = 
1.375, 1.55 (3H each, 2s, Me2C), .2.22 (1H, br s, HO-4), 3.44 (3H, s, MeO-1), 3.60 (1H, dd, J5,5’ = 11.2, 
J4,5’ = 7.8 Hz, H’-5), 3.80 (1H, dd, J4,5 = 4.6 Hz, H-5), 4.00 (1H, dt, J3,4 = 4.2 Hz, H-4), 4.05 (1H, dd, J2,3 
= 6.4, J1,2 = 3.7 Hz, H-2), 4.38 (1H, dd, H-3), 4.57 (1H, d, H-1). 
7b: Colorless prisms, mp 65–66 °C (from AcOEt-hexane) (lit.,17 64–65 °C); Rf = 0.29 (B); 1H NMR20 δ = 
1.37, 1.55 (3H each, 2s, Me2C), .2.30 (1H, br s, HO-2), 3.46 (3H, s, MeO-1), 3.65 (1H, dd, J1,2 = 5.6, J2,3 
= 3.9 Hz, H-2), 3.70 (1H, dd, J5,5’ = 12.9, J4,5’ = 3.2 Hz, H’-5), 3.80 (1H, dd, J4,5 = 3.4 Hz, H-5), 4.27 (1H, 
dt, J3,4 = 6.6 Hz, H-4), 4.48 (1H, dd, H-3), 4.62 (1H, d, H-1). 
B. Acetalization with 2-methoxypropene-TsOH.  To a solution of 6 (200 mg, 1.21 mmol) in dry DMF 
(2.0 mL) were added 2-methoxypropene (0.230 mL, 2.40 mmol) and p-toluenesulfonic acid monohydrate 
(2.0 mg, 0.011 mmol) at 0 °C.  The mixture was stirred at same temperature for 30 min and then worked 
up with the same procedures described above, giving 7a (78.9 mg, 32%) and 7b (154 mg, 62%). 
 
Methyl 2,3-O-isopropylidene-β-D-erythro-pentopyranosid-4-ulose (8).10 
To a solution of oxalyl chloride (1.15 mL, 13.4 mmol) in dry CH2Cl2 (10 mL) was added a solution of 
DMSO (2.00 mL, 27.9 mmol) in dry CH2Cl2 (5.0 mL) at –60 °C.  After stirring for 20 min, a solution of 
7a (1.09 g, 5.34 mmol) in dry CH2Cl2 (5.0 mL) was slowly added at –60 °C.  The mixture was stirred at 
same temperature for 6 h and then TEA (4.70 mL, 33.8 mmol) was added.  The mixture was stirred at rt 
for 30 min, diluted with CHCl3, washed with water, dried (Na2SO4), and evaporated in vacuo.  The 
residue was purified by column chromatography with 2:1 AcOEt-hexane to give 8 (993 mg, 92%) (lit.,10 
94% yield by use of PCC) as a colorless syrup: Rf = 0.64 (B). 
 
Methyl (4S)-4-C-dimethoxyphosphinoyl-2,3-O-isopropylidene-β-D-erythro-pentopyranoside (11). 
DBU (1.15 mL, 7.70 mmol) was dropwise added to a solution of 8 (1.50 g, 7.42 mmol) in dimethyl 
phosphonate (15.0 mL, 163 mmol) at 0 °C and the solution was stirred at rt for 1 h under argon.  The 
mixture was treated with saturated NH4Cl at rt for 1 h and extracted with CHCl3 three times.  The 
combined organic layers were washed with water, dried (Na2SO4), and evaporated in vacuo.  The 
residue was recrystallized with AcOEt and hexane to give 11 (2.27 g, 98%) as colorless needles: mp 
65–66 °C; Rf = 0.48 (C); [α]D25 –38.9° (c 1.10); 1H and 31P NMR, see Table 1; 13C NMR δ = 24.83 and 
26.04 (CMe2), 53.45 and 54.31 [2JC,P = 7.5, 6.3 Hz, P(OMe)2], 55.01 (MeO-1), 60.35 (2J5,P = 9.8 Hz, C-5), 
69.27 (1J4,P = 168.1 Hz, C-4), 70.77 (2J3,P = 1.7 Hz, C-3), 73.34 (3J2,P = 9.8 Hz, C-2), 98.53 (C-1), 109.91 
(CMe2).  Anal. Calcd for C11H21O8P: C, 42.31; H, 6.78.  Found: C, 42.19; H, 6.90. 
 
Methyl 4-deoxy-4-dimethoxyphosphinoyl-2,3-O-isopropylidene-β-D-ribo- (12a) and 
α-L-lyxopyranoside (12b).10 
Methoxalyl chloride (0.800 mL, 8.70 mmol) was added to a solution of 11 (780 mg, 2.50 mmol) and 
DMAP (1.06 g, 8.68 mmol) in dry acetonitrile (20 mL) at 0 °C.  The mixture was stirred at rt for 1 h 
under argon and then poured into water.  Most of the solvent was distilled off in vacuo.  The residue 
 was dissolved in CHCl3, washed with saturated NH4Cl and then with water, dried (Na2SO4), and 
evaporated in vacuo to give the 4-O-methoxalyl derivative as a pale yellow syrup: Rf = 0.78 (C). 
The crude syrup was coevaporated with dry toluene and dissolved in the same solvent (15 mL).  
Tributyltin hydride (1.10 mL, 4.09 mmol) and AIBN (70 mg, 0.43 mmol) were added under argon.  The 
mixture was stirred at 80 °C for 2 h and then concentrated in vacuo.  The residue was separated by 
column chromatography with a gradient eluant of 2:1 AcOEt–hexane to AcOEt to give 12a and 12b. 
12a: Colorless syrup (402 mg, 54%); Rf = 0.26 (C); 1H and 31P NMR, see Table 1; 13C NMR δ = 25.53 
and 27.37 (CMe2), 35.45 (1J4,P = 141.1 Hz, C-4), 52.16 and 53.30 [2JC,P = 6.9, 5.8 Hz, P(OMe)2], 56.49 
(MeO-1), 59.00 (2J5,P = 4.0 Hz, C-5), 70.47 (2J3,P = 7.5 Hz, C-3), 74.86 (3J2,P = 12.1 Hz, C-2), 101.56 
(C-1), 110.22 (CMe2). 
12b: Colorless syrup (134 mg, 18%); Rf = 0.30 (C); 1H and 31P NMR, see Table 1; 13C NMR δ = 26.16 
and 28.15 (CMe2), 37.74 (1J4,P = 139.3 Hz, C-4), 52.49 and 52.75 [2JC,P = 6.4, 6.3 Hz, P(OMe)2], 55.37 
(MeO-1), 56.28 (2J5,P = 1.0 Hz, C-5), 70.35 (2J3,P = 4.0 Hz, C-3), 72.97 (3J2,P = 8.6 Hz, C-2), 99.15 (C-1), 
109.28 (CMe2). 
 
1,2,3,5-Tetra-O-acetyl-4-deoxy-4-methoxyphosphonoyl-D-ribofuranose (13a–d).10 
The following modification of the literature procedures10 was made.  To a solution of 12a (200 mg, 
0.675 mmol) in dry toluene (2.0 mL) was added, with stirring, a solution of SDMA (70% in toluene, 
0.500 mL, 1.80 mmol) in dry toluene (1.0 mL) in small portions at –5 °C under argon.  The stirring was 
continued at 0 °C for 1 h.  Then, water (0.4 mL) was added to decompose excess SDMA and the mixture 
was centrifuged.  The precipitate was extracted with several portions of toluene.  The organic layers 
were combined and evaporated in vacuo, giving the 4-deoxy-4-phosphino derivative as a colorless syrup: 
Rf = 0.68 (C). 
This syrup was immediately treated with 1:1 2-propanol–0.5 M hydrochloric acid (3.0 mL) at 90 °C for 1 
h under argon.  After cooling, the mixture was evaporated in vacuo.  The residue was dissolved in 
2-propanol (2.0 mL), treated with 30% hydrogen peroxide (0.6 mL, 5.9 mmol) at rt for 12 h and then 
concentrated in vacuo to give crude 4-deoxy-4-hydroxyphosphonoyl-D-ribofuranose (4) as a colorless 
syrup. 
This was dissolved in dry pyridine (2.0 mL) and then acetic anhydride (1.0 mL, 11 mmol) was added at 
0 °C.  The mixture was stirred at rt for 12 h, diluted with a small amount of cold water, and concentrated 
in vacuo.  The residue was dissolved in ethanol and passed through a column of Amberlite IR-120(H+) 
(20 mL).  The eluent was evaporated in vacuo and the residue was methylated with ethereal 
diazomethane in dry CH2Cl2 (2.0 mL) at 0 °C.  After evaporation of the solvent, the residue was 
separated by column chromatography with a gradient eluent of 2:1 AcOEt-hexane to AcOEt into three 
fractions A–C. 
Fraction A [Rf = 0.46 (C)] gave the 4-[(R)-methoxyphosphinyl]-β-D-ribofuranose (13b) as colorless syrup 
[31.3 mg, 12% from 12a (lit.,10 6.3%)]. 
Fraction B (Rf = 0.40) gave a colorless syrup (29.8 mg) which consisted of 4-[(R)-P]-α-isomer (13a) 
[6.3% (lit.,10 3.3%)] and 4-[(S)-P]-β-isomer (13d) [5.3% (lit.,10 2.8%)], the ratio being estimated by 1H 
 NMR. 
Fraction C (Rf = 0.35) gave 4-[(S)-P]-α-isomer (13a) as a colorless syrup [8.3 mg, 3.2% (lit.,10 1.7%)]. 
 
Methyl 3-O-benzyl-2-deoxy-β-D-erythro-pentopyranoside (16a) and its 4-O-benzyl isomer (16b).19 
To a solution of 15 (808 mg, 5.45 mmol) in toluene (20 mL) was added dibutyltin oxide (1.40 g, 5.62 
mmol) and the suspension was refluxed under a Dean-Stark trap for 12 h.  After removal of the trap, 
benzyl bromide (0.770 mL, 6.47 mmol) and tetraammonium bromide (1.00 g, 3.10 mmol) were added 
and the mixture was refluxed for 24 h.  The mixture was evaporated in vacuo and the residue was 
separated by column chromatography with 1:2 AcOEt-hexane to give 16a and 16b. 
16a: Colorless syrup (719 mg, 55%); Rf = 0.21 (A); [α]D30 –98.5° (c 1.22) [lit.,19 [α]D27 –81.6° (c 15.4, 
CH2Cl2)]; 1H NMR20 δ = 1.91 (1H, dddd, J2R,2S = 13.2, J2S,3 = 5.0, J1,2S = 2.4, J2S,4 = 1.2 Hz, HS-2), 1.95 
(1H, br s, HO-4), 2.04 (1H, ddd, J2R,3 = 11.0, J1,2R = 3.4 Hz, HR-2), 3.34 (3H, s, MeO-1), 3.75 (1H, dd, 
J5,5’ = 12.5, J4,5’ = 2.3 Hz, H’-5), 3.765 (1H, dd, J4,5 = 2.3 Hz, H-5), 3.87 (1H, ddd, J3,4 = 3.2 Hz, H-3), 
3.92 (1H, dtd, H-4), 4.58, 4.60 (1H each, 2d, 2JH,H = 11.7 Hz, CH2O-3), 4.80 (1H, dd, H-1), 7.30–7.36 
(5H, m, Ph). 
16b: Colorless syrup (522 mg, 40%) (lit.,19 mp 37–39 °C); Rf = 0.27 (A); [α]D30 –125.6° (c 1.48) [lit.,19 
[α]D27 –126.0° (c 7.26, MeOH)];1H NMR20 δ = 1.84 (1H, dddd, J2R,2S = 13.1, J2S,3 = 4.4, J1,2S = 3.4, J2S,4 = 
1.0 Hz, HS-2), 1.95 (1H, br s, HO-4), 1.98 (1H, ddd, J2R,3 = 9.6, J1,2R = 3.2 Hz, HR-2), 3.37 (3H, s, MeO-1), 
3.60 (1H, dddd, J4,5 = 4.5, J4,5’ = 2.2 Hz, H-4), 3.72 (1H, dd, J5,5’ = 12.5 Hz, H’-5), 3.82 (1H, dd, H-5), 
4.05 (1H, ddd, J3,4 = 3.4 Hz, H-3), 4.55, 4.73 (1H each, 2d, 2JH,H = 11.7 Hz, CH2O-3), 4.76 (1H, t, H-1), 
7.30–7.36 (5H, m, Ph). 
 
Methyl 3-O-benzyl-2-deoxy-β-D-glycero-pentopyranosid-4-ulose (17). 
By use of the same procedures described for 8 from 7a, compound (16a) (380 mg, 1.59 mmol) was 
treated with oxalyl chloride (0.400 mL, 4.66 mmol) and DMSO (0.650 mL, 9.07 mmol) in dry CH2Cl2 
(4.0 ml) to give 17 (339 mg, 90%) as a colorless syrup: Rf = 0.25 (A); [α]D30 –166.6° (c 1.05); 1H NMR δ 
= 2.15 (1H, ddd, J2R,2S = 13.0, J2R,3 = 11.7, J1,2R = 3.4 Hz, HR-2), 2.48 (1H, ddd, J2S,3 = 6.8, J1,2S = 2.2 Hz, 
HS-2), 3.42 (3H, s, MeO-1), 3.96 (1H, d , 2J5R,5S = 14.9 Hz, HR-5), 4.17 (1H, d, HS-5), 4.37 (1H, dd, H-3), 
4.57, 4.88 (1H each, 2d, 2JH,H = 11.7 Hz, CH2O-3), 4.92 (1H, dd, H-1), 7.29 [1H, m, Ph(p)], 7.34 [2H, m, 
Ph(m)], 7.37 [2H, m, Ph(o)]; 13C NMR δ = 38.13 (C-2), 55.53 (MeO-1), 67.35 (C-5), 72.65 (CH2O-3), 
74.45 (C-3), 98.55 (C-1), 127.80 [Ph(o)], 127.88 [Ph(p)], 128.45 [Ph(m)], 137.60 [Ph(ipso)], 204.98 (C-4).  
Anal. Calcd for C13H16O4: C, 66.09; H, 6.83.  Found: C, 65.89; H, 6.92. 
 
Methyl (4R)-3-O-benzyl-2-deoxy-4-C-dimethoxyphosphinoyl-β-D-glycero-pentopyranoside (18a) 
and its (4S)-epimer (18b). 
By use of the same procedures described for 11 from 8, compound (17) (550 mg, 2.33 mmol) was treated 
with dimethyl phosphonate (5.0 mL, 54 mmol) and DBU (0.400 mL, 2.68 mmol) to give an inseparable 
mixture (53:47) of 18a,b (750 mg, 93%) as a colorless syrup: Rf = 0.40 (C); 1H and 31P NMR, see Table 1.  
Anal. Calcd for C15H23O7P: C, 52.02; H, 6.69.  Found: C, 52.22; H, 6.51. 
  
Methyl 3-O-benzyl-2,4-dideoxy-4-dimethoxyphosphinoyl-β-D-erythro- (19a) and 
α-L-threo-pentopyranoside (19b). 
By use of the same procedures described for 12 from 11, compounds (18a,b) (500 mg, 1.44 mmol) was 
treated with methoxalyl chloride (0.400 mL, 4.35 mmol) and DMAP (530 mg, 4.34 mmol) in dry 
acetonitrile (10 mL).  The resulting crude syrup [Rf = 0.67 (C)] of the 4-O-methoxalyl derivatives was 
then treated with tributyltin hydride (0.700 mL, 2.60 mmol) and AIBN (45 mg, 0.28 mmol) in dry toluene 
(10 mL).  The products were separated by column chromatography with a gradient eluant of 2:1 
AcOEt-hexane to AcOEt to give 19a and 19b. 
19a: Colorless syrup (251 mg, 53%); Rf = 0.30 (C); 1H and 31P NMR, see Table 1.  Anal. Calcd for 
C15H23O6P: C, 54.54; H, 7.02.  Found: C, 54.63; H, 6.90. 
19b: Colorless syrup (167 mg, 35%); Rf = 0.23 (C); 1H and 31P NMR, see Table 1.  Anal. Calcd for 
C15H23O6P: C, 54.54; H, 7.02.  Found: C, 54.72; H, 7.11. 
 
Methyl 2,4-dideoxy-4-dimethoxyphosphinoyl-β-D-erythro-pentopyranoside (20).11 
To a solution of 19a (200 mg, 0.605 mmol) in methanol (5.0 mL) was added 10% Pd-C (65 mg, 0.061 
mmol).  The mixture was stirred at rt for 12 h under atmospheric pressure of hydrogen.  The catalyst 
was filtered off and the filtrate was evaporated in vacuo.  The residue was purified by short-path column 
chromatography with 1:19 MeOH-CHCl3 to give 20 (131 mg, 90%) as colorless needles: mp 101–102 °C 
(lit.,11 101–102 °C); Rf = 0.05 (C). 
 
1,3,5-Tetra-O-acetyl-2,4-dideoxy-4-methoxyphosphonoyl-D-erythro-pentofuranose (21a–d).11 
The procedures similar to those for the preparation of 13 from 12a were employed.  Thus, compound 
(20) (190 mg, 0.781 mmol) were converted into 21 via 
2,4-dideoxy-4-hydroxyphosphonoyl-D-erythro-pentofuranose (5).  The crude product (21) was separated 
by column chromatography into two fractions. 
The faster-eluting fraction [Rf = 0.44 (C)] gave a colorless syrup (33.7 mg) which consisted of 
4-[(R)-P]-α-isomer (21a) [5.2% (lit.,11 3.9%)] and 4-[(R)-P]-β-isomer (21b) [8.2% (lit.,11 6.1%)], the ratio 
being estimated by 1H NMR. 
The slower-eluting fraction (Rf = 0.39) gave a colorless syrup (42.0 mg) which consisted of 
4-[(S)-P]-α-isomer (21c) [6.8% (lit.,11 5.2%)] and 4-[(S)-P]-β-isomer (21d) [9.9% (lit.,11 7.5%)], the ratio 
being estimated by 1H NMR. 
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